Medical Oncology

Education and Training:

1979

M.D. (Nagoya University School of Medicine)

1988

Ph.D. (Nagoya University)

1988-2000

Research Fellow, Aichi Cancer Center Research Institute

1988-1990

Postdoctoral Fellow, NCI-Navy Medical Oncology Branch, NCI

Positions Held:

1979-1984

Residency and clinical training (Surgery)

1990-1995

Laboratory of Chemotherapy, Aichi Cancer Center Research Institute

1995-2000

Chief, Laboratory of Ultrastructure Research, Aichi Cancer Center

2000-2004

Chief, Division of Molecular Oncology, Aichi Cancer Center

2004-present

Professor, Division of Molecular Carcinogenesis, Center for Neurological Diseases and Cancer, Nagoya University Graduate School of Medicine

Multidirectional dissection of molecular pathogenesis of human solid tumors

Click to zoom

1. Taguchi A et al. Identification of HIF-1α as a novel target for miR-17-92 microRNA cluster. Cancer Res. 68: 5540-5545 (2008)
2. Yanagisawa K et al. A 25-signal proteomic signature and outcome for patients with resected non-small-cell lung cancer. J. Natl. Cancer Inst. 99: 858-867 (2007)
3. Tanaka H et al. Lineage-specific dependency of lung adenocarcinomas on the lung development regulator TTF-1. Cancer Res. 67: 6007-6011 (2007)
4. Ebi H et al. Novel NBS1 heterozygous germline mutation causing MRE11-binding domain loss predisposes to common types of cancer. Cancer Res. 67: 11158-1165 (2007)
5. Takeuchi T et al. Expression profile-defined classification of lung adenocarcinoma shows close relationship with underlying major genetic changes and clinicopathologic behaviors. J. Clin. Oncol. 24: 1679-1688 (2006)
6. Hayashita Y et al. A polycistronic miRNA cluster, miR-17-92, is overexpressed in human lung cancers and enhances cell proliferation. Cancer Res. 65: 9628-9632 (2005)
7. Takamizawa J et al. Reduced expression of the let-7 microRNAs in human lung cancers in association with shortened postoperative survival. Cancer Res. 64: 3753-3756 (2004)
8. He Y et al. Suppression of tumor lymphangiogenesis and lymph node metastasis by blocking vascular endothelial growth factor receptor 3 signaling. J. Natl. Cancer Inst. 94: 819-825 (2002)
9. Kozaki K et al. Establishment and characterization of a human lung cancer cell line NCI-H460-LNM35 with consistent lymphogenous metastasis via both subcutaneous and orthotopic propagation. Cancer Res. 60: 2535-2540 (2000)
10. Hida T et al. Increased expression of cyclooxygenase 2 frequently occurs in human lung cancers, specifically in adenocarcinomas. Cancer Res. 58: 3761-3764 (1998)
11. Mitsudomi T et al. Clinical implications of p53 autoantibodies in the sera of patients with non-small-cell lung cancer. J. Natl. Cancer Inst. 90: 1563-1568 (1998)
12. Masuda A et al. Establishment of human peripheral lung epithelial cell lines (HPL1) retaining differentiated characteristics and responsiveness to EGF, HGF and TGF-b. Cancer Res. 57: 4898-4904 (1997)
13. Nishio M et al. Prognostic significance of abnormal p53 accumulation in primary, resected non-small cell lung cancers. J. Clin. Oncol. 14: 497-502 (1996)
14. Suzuki H et al. Altered imprinting in lung cancer. Nature Genet. 6: 332-333 (1994)
15. Suzuki H et al. p53 mutations in non-small cell lung cancer in Japan: Association between mutations and smoking. Cancer Res. 52: 734-736 (1992)
16. Takahashi T et al. Identification of intronic point mutations as an alternative mechanism for p53 inactivation in lung cancer. J. Clin. Invest. 86: 363-369 (1990)
17. Takahashi T et al. p53: a frequent target for genetic abnormalities in lung cancer. Science 246: 491-494 (1989)

1993.10 Incitement Award of the Japanese Cancer Association